J. A. Engelman

2.0k total citations
24 papers, 1.3k citations indexed

About

J. A. Engelman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. A. Engelman has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in J. A. Engelman's work include Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). J. A. Engelman is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). J. A. Engelman collaborates with scholars based in United States and Norway. J. A. Engelman's co-authors include Pasi A. Jänne, Lecia V. Sequist, Kreshnik Zejnullahu, Kristopher T. Kahle, Victoria A. Joshi, April F. Eichler, Thomas J. Lynch, Henning Willers, B.Y. Yeap and Lewis C. Cantley and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

J. A. Engelman

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. A. Engelman United States	12	1.0k	834	511	257	119	24	1.3k
Marissa N. Balak United States	7	979 1.0×	872 1.0×	701 1.4×	235 0.9×	140 1.2×	7	1.3k
Aleksandra Markovets United States	16	1.1k 1.1×	834 1.0×	573 1.1×	392 1.5×	127 1.1×	39	1.4k
Georgiana Kuhlmann United States	5	920 0.9×	753 0.9×	500 1.0×	357 1.4×	109 0.9×	6	1.3k
Nicholas A. Jessop United States	6	959 0.9×	843 1.0×	676 1.3×	289 1.1×	211 1.8×	9	1.3k
Dana Ghiorghiu United Kingdom	15	929 0.9×	808 1.0×	497 1.0×	171 0.7×	86 0.7×	36	1.4k
Masaki Shimoji Japan	15	775 0.8×	676 0.8×	434 0.8×	204 0.8×	93 0.8×	38	1.1k
Jaromı́r Roubec Czechia	9	1.3k 1.2×	1.3k 1.5×	574 1.1×	170 0.7×	75 0.6×	23	1.7k
Jacqui Rowbottom United Kingdom	10	791 0.8×	1.2k 1.5×	567 1.1×	321 1.2×	127 1.1×	14	1.6k
Akito Hata Japan	25	1.4k 1.4×	1.1k 1.3×	320 0.6×	325 1.3×	85 0.7×	117	1.7k
Stephanie Cardarella United States	11	901 0.9×	573 0.7×	431 0.8×	303 1.2×	130 1.1×	13	1.1k

Countries citing papers authored by J. A. Engelman

Since Specialization

Citations

This map shows the geographic impact of J. A. Engelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Engelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Engelman more than expected).

Fields of papers citing papers by J. A. Engelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Engelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Engelman. The network helps show where J. A. Engelman may publish in the future.

Co-authorship network of co-authors of J. A. Engelman

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Engelman. A scholar is included among the top collaborators of J. A. Engelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Engelman. J. A. Engelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raoof, Sana, et al.. (2018). Abstract A142: Targeting FGFR to overcome EMT-related resistance in EGFR-mutated non-small cell lung cancer. Molecular Cancer Therapeutics. 17(1_Supplement). A142–A142. 1 indexed citations

Gainor, Justin F., Leila Dardaei, Satoshi Yoda, et al.. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. European Journal of Cancer. 69. S138–S138. 119 indexed citations

Piotrowska, Zofia, Matthew J. Niederst, Mari Mino–Kenudson, et al.. (2014). Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy. International Journal of Radiation Oncology*Biology*Physics. 90(5). S6–S7. 12 indexed citations

Reckamp, Karen L., Giuseppe Giaccone, D. Ross Camidge, et al.. (2014). A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 120(8). 1145–1154. 120 indexed citations

Camidge, D. Ross, J. A. Engelman, J. Clark, et al.. (2012). Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement. Annals of Oncology. 23. ix389–ix389. 16 indexed citations

Corcoran, Ryan B., Ka‐Wing Cheng, Aaron N. Hata, et al.. (2012). 149 Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models. European Journal of Cancer. 48. 46–46. 2 indexed citations

Habben, Kai, Paul Delmar, Carrie Brownstein, et al.. (2011). Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 7584–7584. 8 indexed citations

Kris, Mark G., B. E. Johnson, D J Kwiatkowski, et al.. (2011). Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).. Journal of Clinical Oncology. 29(15_suppl). CRA7506–CRA7506. 176 indexed citations

Sequist, Lecia V., Rebecca S. Heist, Alice T. Shaw, et al.. (2011). SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.. Journal of Clinical Oncology. 29(15_suppl). 7518–7518. 4 indexed citations

10.

Yonesaka, Kimio, Kreshnik Zejnullahu, Isamu Okamoto, et al.. (2011). OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 47. S10–S10. 80 indexed citations

11.

Johnson, Bruce E., Mark G. Kris, D J Kwiatkowski, et al.. (2011). 9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC). European Journal of Cancer. 47. S597–S597. 8 indexed citations

12.

Eichler, April F., Kristopher T. Kahle, Victoria A. Joshi, et al.. (2010). EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology. 12(11). 1193–1199. 213 indexed citations

13.

Shaw, Alice T., B.Y. Yeap, Daniel B. Costa, et al.. (2010). Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7606–7606. 11 indexed citations

14.

Cohen, Richard B., Pasi A. Jänne, J. A. Engelman, et al.. (2010). A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3015–3015. 21 indexed citations

15.

Waltman, Belinda A., Dora Dias‐Santagata, Arjola K. Cosper, et al.. (2010). SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 28(15_suppl). 7554–7554. 1 indexed citations

16.

Heist, Rebecca S., D. Sahani, Nathan A. Pennell, et al.. (2010). In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7612–7612. 2 indexed citations

17.

Wakelee, Heather A., Scott Gettinger, J. A. Engelman, et al.. (2010). A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 3017–3017. 55 indexed citations

18.

Jänne, Pasi A., et al.. (2008). 552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design. European Journal of Cancer Supplements. 6(12). 174–174. 12 indexed citations

19.

Engelman, J. A., Toru Mukohara, Kreshnik Zejnullahu, et al.. (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation. 116(10). 2695–2706. 374 indexed citations

20.

Mukohara, Toru, J. A. Engelman, Joseph Pearlberg, et al.. (2005). O-009 Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines. Lung Cancer. 49. S7–S7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact